- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03937856
Recruitment Status Terminated (PI is leaving the institution)
First Posted May 6, 2019
Last update posted April 26, 2021
This study will assess the effect of a mindfulness meditation program administered via a smartphone application on health-related quality of life for patients with rheumatic disease.
After obtaining written consent, participants will be asked to download and use the Calm meditation smartphone application everyday for a 30-day period. Participant demographics and clinical information will be collected at baseline. Participants will additionally be asked to complete questionnaires concerning health-related quality of life (HRQoL) as well as mental health, stress, and self-efficacy at baseline and at the end of the 30 day study period. A brief check-in via telephone will be conducted on day 15. Participants using the calm app will be compared to participants receiving usual care who will be asked to complete identical sets of questionnaires. The participant may choose whether they join the Calm application vs usual care (questionnaires only) group on a voluntary basis; there is no pre-assignment. The Calm application is a publicly available program that is available to any patient independent of this study.
|Experimental: Intervention group
Participant groups will include enrolled patients with rheumatic disease who use the smartphone mindfulness meditation application for 30 days.
Behavioral: Calm- Mindfulness Meditation smartphone application
Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
Established patients of the Johns Hopkins (JH) Rheumatology Division will be eligible for
- Participants must have one of the following JH rheumatologist-diagnosed and/or
confirmed diseases: inflammatory arthritis, scleroderma, myositis, Sjogren's syndrome,
systemic lupus erythematosus, and vasculitis.
- Participants must be at least 18 years of age to participate; there is no upper-bound
- Participants must have access to a smartphone or computer to access the Calm app (or
webpage) as well as Redcap (which requires an email address) to access the
United States, Maryland
Johns Hopkins Bayview
Johns Hopkins University
Principal Investigator: Dana DiRenzo, MD Johns Hopkins University